nodes	percent_of_prediction	percent_of_DWPC	metapath
Clodronate—PTGS2—bone cancer	0.741	1	CbGaD
Clodronate—PTGS2—Cisplatin—bone cancer	0.0179	1	CbGbCtD
Clodronate—SLC25A5—Electron Transport Chain—NDUFA12—bone cancer	0.009	0.119	CbGpPWpGaD
Clodronate—Myeloid leukaemia—Epirubicin—bone cancer	0.00766	0.0629	CcSEcCtD
Clodronate—SLC25A6—Electron Transport Chain—NDUFA12—bone cancer	0.00754	0.1	CbGpPWpGaD
Clodronate—Myeloid leukaemia—Doxorubicin—bone cancer	0.00708	0.0582	CcSEcCtD
Clodronate—Extravasation—Carboplatin—bone cancer	0.00611	0.0502	CcSEcCtD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—FEV—bone cancer	0.00609	0.0808	CbGpPWpGaD
Clodronate—SLC25A4—Electron Transport Chain—NDUFA12—bone cancer	0.00589	0.0781	CbGpPWpGaD
Clodronate—Acute leukaemia—Cisplatin—bone cancer	0.00547	0.0449	CcSEcCtD
Clodronate—Acute myeloid leukaemia—Epirubicin—bone cancer	0.00489	0.0402	CcSEcCtD
Clodronate—Acute myeloid leukaemia—Doxorubicin—bone cancer	0.00453	0.0372	CcSEcCtD
Clodronate—SLC25A6—connective tissue—bone cancer	0.00433	0.0986	CbGeAlD
Clodronate—PTGS2—periosteum—bone cancer	0.00407	0.0927	CbGeAlD
Clodronate—SLC25A5—connective tissue—bone cancer	0.00376	0.0858	CbGeAlD
Clodronate—SLC25A5—Regulation of insulin secretion—GNA11—bone cancer	0.00357	0.0474	CbGpPWpGaD
Clodronate—PTGS2—leg—bone cancer	0.00324	0.0739	CbGeAlD
Clodronate—SLC25A6—Regulation of insulin secretion—GNA11—bone cancer	0.003	0.0397	CbGpPWpGaD
Clodronate—PTGS2—hindlimb—bone cancer	0.00289	0.066	CbGeAlD
Clodronate—SLC25A6—bone marrow—bone cancer	0.00288	0.0657	CbGeAlD
Clodronate—SLC25A6—spinal cord—bone cancer	0.00287	0.0654	CbGeAlD
Clodronate—PTGS2—cartilage tissue—bone cancer	0.00285	0.065	CbGeAlD
Clodronate—Acute leukaemia—Epirubicin—bone cancer	0.00281	0.0231	CcSEcCtD
Clodronate—SLC25A5—Integration of energy metabolism—GNA11—bone cancer	0.00281	0.0373	CbGpPWpGaD
Clodronate—Acute leukaemia—Doxorubicin—bone cancer	0.0026	0.0213	CcSEcCtD
Clodronate—SLC25A5—tendon—bone cancer	0.00259	0.059	CbGeAlD
Clodronate—Serum creatinine increased—Cisplatin—bone cancer	0.00254	0.0209	CcSEcCtD
Clodronate—SLC25A5—bone marrow—bone cancer	0.00251	0.0571	CbGeAlD
Clodronate—SLC25A5—spinal cord—bone cancer	0.0025	0.0569	CbGeAlD
Clodronate—PTGS2—appendage—bone cancer	0.00248	0.0566	CbGeAlD
Clodronate—SLC25A4—tendon—bone cancer	0.00242	0.0553	CbGeAlD
Clodronate—SLC25A6—Integration of energy metabolism—GNA11—bone cancer	0.00236	0.0312	CbGpPWpGaD
Clodronate—Hyperphosphataemia—Epirubicin—bone cancer	0.00235	0.0193	CcSEcCtD
Clodronate—SLC25A4—spinal cord—bone cancer	0.00234	0.0533	CbGeAlD
Clodronate—SLC25A4—Regulation of insulin secretion—GNA11—bone cancer	0.00234	0.031	CbGpPWpGaD
Clodronate—Hyperphosphataemia—Doxorubicin—bone cancer	0.00218	0.0179	CcSEcCtD
Clodronate—Infection—Carboplatin—bone cancer	0.00189	0.0155	CcSEcCtD
Clodronate—SLC25A4—Integration of energy metabolism—GNA11—bone cancer	0.00184	0.0244	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism of proteins—MOGS—bone cancer	0.00182	0.0241	CbGpPWpGaD
Clodronate—Extravasation—Cisplatin—bone cancer	0.00179	0.0147	CcSEcCtD
Clodronate—Hepatocellular injury—Cisplatin—bone cancer	0.00156	0.0128	CcSEcCtD
Clodronate—Wheezing—Cisplatin—bone cancer	0.00152	0.0125	CcSEcCtD
Clodronate—Local reaction—Epirubicin—bone cancer	0.00145	0.0119	CcSEcCtD
Clodronate—SLC25A4—Metabolism of proteins—MOGS—bone cancer	0.00142	0.0188	CbGpPWpGaD
Clodronate—Local reaction—Doxorubicin—bone cancer	0.00134	0.011	CcSEcCtD
Clodronate—Serum creatinine increased—Epirubicin—bone cancer	0.00131	0.0107	CcSEcCtD
Clodronate—Liver disorder—Methotrexate—bone cancer	0.00126	0.0103	CcSEcCtD
Clodronate—Renal failure acute—Cisplatin—bone cancer	0.00123	0.0101	CcSEcCtD
Clodronate—Serum creatinine increased—Doxorubicin—bone cancer	0.00121	0.00992	CcSEcCtD
Clodronate—Hypercalcaemia—Epirubicin—bone cancer	0.00116	0.00949	CcSEcCtD
Clodronate—Hypercalcaemia—Doxorubicin—bone cancer	0.00107	0.00878	CcSEcCtD
Clodronate—Blood creatinine increased—Cisplatin—bone cancer	0.00106	0.00873	CcSEcCtD
Clodronate—Dehydration—Cisplatin—bone cancer	0.00106	0.00867	CcSEcCtD
Clodronate—SLC25A5—Metabolism—NDUFA12—bone cancer	0.00102	0.0135	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism of proteins—TUBB4B—bone cancer	0.000995	0.0132	CbGpPWpGaD
Clodronate—Extravasation—Methotrexate—bone cancer	0.000984	0.00807	CcSEcCtD
Clodronate—Proteinuria—Methotrexate—bone cancer	0.000977	0.00802	CcSEcCtD
Clodronate—Protein urine present—Methotrexate—bone cancer	0.000963	0.00791	CcSEcCtD
Clodronate—Neoplasm malignant—Epirubicin—bone cancer	0.000941	0.00772	CcSEcCtD
Clodronate—Oliguria—Methotrexate—bone cancer	0.000931	0.00764	CcSEcCtD
Clodronate—Extravasation—Epirubicin—bone cancer	0.000921	0.00756	CcSEcCtD
Clodronate—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL3—bone cancer	0.000915	0.0121	CbGpPWpGaD
Clodronate—Hypocalcaemia—Epirubicin—bone cancer	0.000877	0.0072	CcSEcCtD
Clodronate—Oliguria—Epirubicin—bone cancer	0.000872	0.00715	CcSEcCtD
Clodronate—Neoplasm malignant—Doxorubicin—bone cancer	0.00087	0.00714	CcSEcCtD
Clodronate—Renal failure—Cisplatin—bone cancer	0.00086	0.00706	CcSEcCtD
Clodronate—SLC25A6—Metabolism of proteins—TUBB2A—bone cancer	0.000859	0.0114	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—NDUFA12—bone cancer	0.000856	0.0113	CbGpPWpGaD
Clodronate—Extravasation—Doxorubicin—bone cancer	0.000852	0.00699	CcSEcCtD
Clodronate—SLC25A5—Metabolism—NT5C3A—bone cancer	0.000846	0.0112	CbGpPWpGaD
Clodronate—Creatinine increased—Epirubicin—bone cancer	0.000844	0.00693	CcSEcCtD
Clodronate—Hypocalcaemia—Doxorubicin—bone cancer	0.000812	0.00666	CcSEcCtD
Clodronate—PTGS2—Signaling mediated by p38-alpha and p38-beta—ATF1—bone cancer	0.000808	0.0107	CbGpPWpGaD
Clodronate—Oliguria—Doxorubicin—bone cancer	0.000806	0.00662	CcSEcCtD
Clodronate—Hepatocellular injury—Epirubicin—bone cancer	0.000803	0.00659	CcSEcCtD
Clodronate—Creatinine increased—Doxorubicin—bone cancer	0.000781	0.00641	CcSEcCtD
Clodronate—SLC25A4—Metabolism of proteins—TUBB4B—bone cancer	0.000777	0.0103	CbGpPWpGaD
Clodronate—Urinary tract disorder—Cisplatin—bone cancer	0.000776	0.00637	CcSEcCtD
Clodronate—Connective tissue disorder—Cisplatin—bone cancer	0.000772	0.00634	CcSEcCtD
Clodronate—Urethral disorder—Cisplatin—bone cancer	0.00077	0.00632	CcSEcCtD
Clodronate—Hepatocellular injury—Doxorubicin—bone cancer	0.000743	0.0061	CcSEcCtD
Clodronate—SLC25A6—Metabolism—NT5C3A—bone cancer	0.000709	0.0094	CbGpPWpGaD
Clodronate—PTGS2—connective tissue—bone cancer	0.000709	0.0162	CbGeAlD
Clodronate—Mediastinal disorder—Cisplatin—bone cancer	0.000708	0.00581	CcSEcCtD
Clodronate—Renal failure acute—Methotrexate—bone cancer	0.000675	0.00554	CcSEcCtD
Clodronate—SLC25A4—Metabolism of proteins—TUBB2A—bone cancer	0.00067	0.00889	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—NDUFA12—bone cancer	0.000668	0.00886	CbGpPWpGaD
Clodronate—Hepatic function abnormal—Epirubicin—bone cancer	0.000667	0.00548	CcSEcCtD
Clodronate—Anaemia—Cisplatin—bone cancer	0.000632	0.00519	CcSEcCtD
Clodronate—Renal failure acute—Epirubicin—bone cancer	0.000631	0.00518	CcSEcCtD
Clodronate—Hepatic function abnormal—Doxorubicin—bone cancer	0.000617	0.00507	CcSEcCtD
Clodronate—Renal impairment—Epirubicin—bone cancer	0.000613	0.00503	CcSEcCtD
Clodronate—SLC25A6—Metabolism of proteins—EIF2S1—bone cancer	0.000599	0.00794	CbGpPWpGaD
Clodronate—Cardiac failure—Epirubicin—bone cancer	0.000597	0.0049	CcSEcCtD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL3—bone cancer	0.000592	0.00785	CbGpPWpGaD
Clodronate—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—bone cancer	0.000589	0.0078	CbGpPWpGaD
Clodronate—Renal failure acute—Doxorubicin—bone cancer	0.000584	0.0048	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000578	0.00475	CcSEcCtD
Clodronate—Renal impairment—Doxorubicin—bone cancer	0.000567	0.00465	CcSEcCtD
Clodronate—Infection—Cisplatin—bone cancer	0.000554	0.00455	CcSEcCtD
Clodronate—SLC25A4—Metabolism—NT5C3A—bone cancer	0.000554	0.00734	CbGpPWpGaD
Clodronate—Cardiac failure—Doxorubicin—bone cancer	0.000553	0.00454	CcSEcCtD
Clodronate—Blood creatinine increased—Epirubicin—bone cancer	0.000546	0.00448	CcSEcCtD
Clodronate—Dehydration—Epirubicin—bone cancer	0.000542	0.00445	CcSEcCtD
Clodronate—Skin disorder—Cisplatin—bone cancer	0.000542	0.00445	CcSEcCtD
Clodronate—Abdominal pain upper—Epirubicin—bone cancer	0.000532	0.00437	CcSEcCtD
Clodronate—Anorexia—Cisplatin—bone cancer	0.000532	0.00437	CcSEcCtD
Clodronate—Alanine aminotransferase increased—Epirubicin—bone cancer	0.000514	0.00422	CcSEcCtD
Clodronate—Blood creatinine increased—Doxorubicin—bone cancer	0.000505	0.00415	CcSEcCtD
Clodronate—Dysphagia—Epirubicin—bone cancer	0.000504	0.00414	CcSEcCtD
Clodronate—Dehydration—Doxorubicin—bone cancer	0.000502	0.00412	CcSEcCtD
Clodronate—Dyspnoea—Cisplatin—bone cancer	0.000497	0.00408	CcSEcCtD
Clodronate—Abdominal pain upper—Doxorubicin—bone cancer	0.000493	0.00404	CcSEcCtD
Clodronate—PTGS2—tendon—bone cancer	0.000487	0.0111	CbGeAlD
Clodronate—Decreased appetite—Cisplatin—bone cancer	0.000485	0.00398	CcSEcCtD
Clodronate—Pneumonia—Methotrexate—bone cancer	0.000483	0.00396	CcSEcCtD
Clodronate—Gastrointestinal disorder—Cisplatin—bone cancer	0.000482	0.00395	CcSEcCtD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—JUN—bone cancer	0.000481	0.00638	CbGpPWpGaD
Clodronate—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000476	0.00391	CcSEcCtD
Clodronate—Renal failure—Methotrexate—bone cancer	0.000472	0.00387	CcSEcCtD
Clodronate—PTGS2—bone marrow—bone cancer	0.000472	0.0108	CbGeAlD
Clodronate—PTGS2—spinal cord—bone cancer	0.00047	0.0107	CbGeAlD
Clodronate—SLC25A4—Metabolism of proteins—EIF2S1—bone cancer	0.000468	0.0062	CbGpPWpGaD
Clodronate—Dysphagia—Doxorubicin—bone cancer	0.000466	0.00383	CcSEcCtD
Clodronate—Pneumonia—Epirubicin—bone cancer	0.000452	0.00371	CcSEcCtD
Clodronate—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—DHFR—bone cancer	0.000449	0.00595	CbGpPWpGaD
Clodronate—SLC25A5—Disease—ENO2—bone cancer	0.000443	0.00587	CbGpPWpGaD
Clodronate—Renal failure—Epirubicin—bone cancer	0.000442	0.00363	CcSEcCtD
Clodronate—Pharyngitis—Methotrexate—bone cancer	0.000428	0.00351	CcSEcCtD
Clodronate—Urinary tract disorder—Methotrexate—bone cancer	0.000426	0.00349	CcSEcCtD
Clodronate—Urethral disorder—Methotrexate—bone cancer	0.000422	0.00347	CcSEcCtD
Clodronate—Pneumonia—Doxorubicin—bone cancer	0.000418	0.00343	CcSEcCtD
Clodronate—SLC25A5—Disease—DHFR—bone cancer	0.000411	0.00544	CbGpPWpGaD
Clodronate—Renal failure—Doxorubicin—bone cancer	0.000409	0.00335	CcSEcCtD
Clodronate—Pharyngitis—Epirubicin—bone cancer	0.0004	0.00329	CcSEcCtD
Clodronate—Urinary tract disorder—Epirubicin—bone cancer	0.000398	0.00327	CcSEcCtD
Clodronate—Connective tissue disorder—Epirubicin—bone cancer	0.000396	0.00325	CcSEcCtD
Clodronate—Urethral disorder—Epirubicin—bone cancer	0.000395	0.00325	CcSEcCtD
Clodronate—Mediastinal disorder—Methotrexate—bone cancer	0.000388	0.00319	CcSEcCtD
Clodronate—Diarrhoea—Cisplatin—bone cancer	0.000382	0.00313	CcSEcCtD
Clodronate—SLC25A6—Disease—ENO2—bone cancer	0.000371	0.00492	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—ENO2—bone cancer	0.000371	0.00491	CbGpPWpGaD
Clodronate—Pharyngitis—Doxorubicin—bone cancer	0.00037	0.00304	CcSEcCtD
Clodronate—Urinary tract disorder—Doxorubicin—bone cancer	0.000369	0.00303	CcSEcCtD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—bone cancer	0.000367	0.00487	CbGpPWpGaD
Clodronate—Connective tissue disorder—Doxorubicin—bone cancer	0.000367	0.00301	CcSEcCtD
Clodronate—Urethral disorder—Doxorubicin—bone cancer	0.000366	0.003	CcSEcCtD
Clodronate—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—bone cancer	0.000366	0.00485	CbGpPWpGaD
Clodronate—Mediastinal disorder—Epirubicin—bone cancer	0.000363	0.00298	CcSEcCtD
Clodronate—Vomiting—Cisplatin—bone cancer	0.000355	0.00291	CcSEcCtD
Clodronate—Rash—Cisplatin—bone cancer	0.000352	0.00289	CcSEcCtD
Clodronate—Dermatitis—Cisplatin—bone cancer	0.000351	0.00289	CcSEcCtD
Clodronate—Anaemia—Methotrexate—bone cancer	0.000347	0.00285	CcSEcCtD
Clodronate—SLC25A6—Disease—DHFR—bone cancer	0.000344	0.00456	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—DHFR—bone cancer	0.000344	0.00456	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000341	0.00452	CbGpPWpGaD
Clodronate—Mediastinal disorder—Doxorubicin—bone cancer	0.000336	0.00276	CcSEcCtD
Clodronate—Nausea—Cisplatin—bone cancer	0.000331	0.00272	CcSEcCtD
Clodronate—Anaemia—Epirubicin—bone cancer	0.000325	0.00266	CcSEcCtD
Clodronate—SLC25A5—Metabolism—GNA11—bone cancer	0.000321	0.00426	CbGpPWpGaD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000317	0.0026	CcSEcCtD
Clodronate—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—bone cancer	0.000315	0.00417	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—ENO2—bone cancer	0.000311	0.00412	CbGpPWpGaD
Clodronate—Infection—Methotrexate—bone cancer	0.000304	0.0025	CcSEcCtD
Clodronate—Anaemia—Doxorubicin—bone cancer	0.0003	0.00246	CcSEcCtD
Clodronate—SLC25A5—Disease—TGFBR2—bone cancer	0.000298	0.00394	CbGpPWpGaD
Clodronate—Skin disorder—Methotrexate—bone cancer	0.000297	0.00244	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000297	0.00244	CcSEcCtD
Clodronate—Anorexia—Methotrexate—bone cancer	0.000292	0.0024	CcSEcCtD
Clodronate—SLC25A5—Metabolism—CYP3A4—bone cancer	0.000291	0.00386	CbGpPWpGaD
Clodronate—SLC25A4—Disease—ENO2—bone cancer	0.00029	0.00384	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—DHFR—bone cancer	0.000288	0.00382	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000287	0.00381	CbGpPWpGaD
Clodronate—Infection—Epirubicin—bone cancer	0.000285	0.00234	CcSEcCtD
Clodronate—Skin disorder—Epirubicin—bone cancer	0.000278	0.00228	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000275	0.00225	CcSEcCtD
Clodronate—Anorexia—Epirubicin—bone cancer	0.000273	0.00224	CcSEcCtD
Clodronate—Dyspnoea—Methotrexate—bone cancer	0.000273	0.00224	CcSEcCtD
Clodronate—Dyspepsia—Methotrexate—bone cancer	0.00027	0.00221	CcSEcCtD
Clodronate—SLC25A6—Metabolism—GNA11—bone cancer	0.000269	0.00357	CbGpPWpGaD
Clodronate—SLC25A4—Disease—DHFR—bone cancer	0.000269	0.00356	CbGpPWpGaD
Clodronate—Decreased appetite—Methotrexate—bone cancer	0.000266	0.00219	CcSEcCtD
Clodronate—Gastrointestinal disorder—Methotrexate—bone cancer	0.000264	0.00217	CcSEcCtD
Clodronate—Infection—Doxorubicin—bone cancer	0.000263	0.00216	CcSEcCtD
Clodronate—Skin disorder—Doxorubicin—bone cancer	0.000258	0.00211	CcSEcCtD
Clodronate—Dyspnoea—Epirubicin—bone cancer	0.000255	0.0021	CcSEcCtD
Clodronate—Anorexia—Doxorubicin—bone cancer	0.000253	0.00207	CcSEcCtD
Clodronate—Dyspepsia—Epirubicin—bone cancer	0.000252	0.00207	CcSEcCtD
Clodronate—SLC25A6—Disease—TGFBR2—bone cancer	0.000249	0.00331	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—GSTP1—bone cancer	0.000249	0.0033	CbGpPWpGaD
Clodronate—Decreased appetite—Epirubicin—bone cancer	0.000249	0.00204	CcSEcCtD
Clodronate—Gastrointestinal disorder—Epirubicin—bone cancer	0.000247	0.00203	CcSEcCtD
Clodronate—SLC25A6—Metabolism of proteins—MMP2—bone cancer	0.000245	0.00325	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000244	0.00324	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—CYP3A4—bone cancer	0.000244	0.00324	CbGpPWpGaD
Clodronate—Urticaria—Methotrexate—bone cancer	0.000243	0.002	CcSEcCtD
Clodronate—SLC25A4—Metabolism—ENO2—bone cancer	0.000242	0.00321	CbGpPWpGaD
Clodronate—Abdominal pain—Methotrexate—bone cancer	0.000242	0.00199	CcSEcCtD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—bone cancer	0.000237	0.00314	CbGpPWpGaD
Clodronate—Dyspnoea—Doxorubicin—bone cancer	0.000236	0.00194	CcSEcCtD
Clodronate—Dyspepsia—Doxorubicin—bone cancer	0.000233	0.00192	CcSEcCtD
Clodronate—Decreased appetite—Doxorubicin—bone cancer	0.00023	0.00189	CcSEcCtD
Clodronate—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000229	0.00188	CcSEcCtD
Clodronate—PTGS2—C-MYB transcription factor network—KIT—bone cancer	0.000228	0.00302	CbGpPWpGaD
Clodronate—Urticaria—Epirubicin—bone cancer	0.000228	0.00187	CcSEcCtD
Clodronate—Abdominal pain—Epirubicin—bone cancer	0.000227	0.00186	CcSEcCtD
Clodronate—SLC25A4—Metabolism—DHFR—bone cancer	0.000225	0.00298	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000223	0.00295	CbGpPWpGaD
Clodronate—Pruritus—Methotrexate—bone cancer	0.000217	0.00178	CcSEcCtD
Clodronate—Urticaria—Doxorubicin—bone cancer	0.000211	0.00173	CcSEcCtD
Clodronate—SLC25A4—Metabolism—GNA11—bone cancer	0.00021	0.00279	CbGpPWpGaD
Clodronate—Abdominal pain—Doxorubicin—bone cancer	0.00021	0.00172	CcSEcCtD
Clodronate—Diarrhoea—Methotrexate—bone cancer	0.000209	0.00172	CcSEcCtD
Clodronate—SLC25A6—Metabolism—GSTP1—bone cancer	0.000209	0.00277	CbGpPWpGaD
Clodronate—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—bone cancer	0.000208	0.00275	CbGpPWpGaD
Clodronate—SLC25A5—Disease—KIT—bone cancer	0.000203	0.00269	CbGpPWpGaD
Clodronate—Pruritus—Epirubicin—bone cancer	0.000203	0.00166	CcSEcCtD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000203	0.00269	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.0002	0.00265	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.000199	0.00264	CbGpPWpGaD
Clodronate—Diarrhoea—Epirubicin—bone cancer	0.000196	0.00161	CcSEcCtD
Clodronate—Vomiting—Methotrexate—bone cancer	0.000195	0.0016	CcSEcCtD
Clodronate—SLC25A4—Disease—TGFBR2—bone cancer	0.000195	0.00258	CbGpPWpGaD
Clodronate—Rash—Methotrexate—bone cancer	0.000193	0.00158	CcSEcCtD
Clodronate—Dermatitis—Methotrexate—bone cancer	0.000193	0.00158	CcSEcCtD
Clodronate—SLC25A4—Metabolism of proteins—MMP2—bone cancer	0.000191	0.00254	CbGpPWpGaD
Clodronate—SLC25A5—Disease—BRAF—bone cancer	0.000191	0.00253	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—CYP3A4—bone cancer	0.000191	0.00253	CbGpPWpGaD
Clodronate—Pruritus—Doxorubicin—bone cancer	0.000188	0.00154	CcSEcCtD
Clodronate—PTGS2—Spinal Cord Injury—CDK4—bone cancer	0.000185	0.00245	CbGpPWpGaD
Clodronate—Vomiting—Epirubicin—bone cancer	0.000182	0.0015	CcSEcCtD
Clodronate—Nausea—Methotrexate—bone cancer	0.000182	0.00149	CcSEcCtD
Clodronate—Diarrhoea—Doxorubicin—bone cancer	0.000181	0.00149	CcSEcCtD
Clodronate—Rash—Epirubicin—bone cancer	0.000181	0.00148	CcSEcCtD
Clodronate—Dermatitis—Epirubicin—bone cancer	0.000181	0.00148	CcSEcCtD
Clodronate—Nausea—Epirubicin—bone cancer	0.00017	0.0014	CcSEcCtD
Clodronate—SLC25A6—Disease—KIT—bone cancer	0.00017	0.00226	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000169	0.00225	CbGpPWpGaD
Clodronate—Vomiting—Doxorubicin—bone cancer	0.000169	0.00138	CcSEcCtD
Clodronate—Rash—Doxorubicin—bone cancer	0.000167	0.00137	CcSEcCtD
Clodronate—Dermatitis—Doxorubicin—bone cancer	0.000167	0.00137	CcSEcCtD
Clodronate—SLC25A4—Metabolism—GSTP1—bone cancer	0.000163	0.00216	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—RB1—bone cancer	0.000161	0.00213	CbGpPWpGaD
Clodronate—SLC25A6—Disease—BRAF—bone cancer	0.00016	0.00212	CbGpPWpGaD
Clodronate—SLC25A5—Disease—MDM2—bone cancer	0.00016	0.00212	CbGpPWpGaD
Clodronate—Nausea—Doxorubicin—bone cancer	0.000157	0.00129	CcSEcCtD
Clodronate—SLC25A5—Disease—PTGS2—bone cancer	0.000154	0.00204	CbGpPWpGaD
Clodronate—SLC25A6—Disease—MDM2—bone cancer	0.000134	0.00178	CbGpPWpGaD
Clodronate—SLC25A4—Disease—KIT—bone cancer	0.000133	0.00176	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—NDUFA12—bone cancer	0.000132	0.00175	CbGpPWpGaD
Clodronate—SLC25A6—Disease—PTGS2—bone cancer	0.000129	0.00171	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—PTGS2—bone cancer	0.000129	0.00171	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.000126	0.00167	CbGpPWpGaD
Clodronate—SLC25A4—Disease—BRAF—bone cancer	0.000125	0.00166	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—MMP9—bone cancer	0.000116	0.00153	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—NT5C3A—bone cancer	0.000109	0.00145	CbGpPWpGaD
Clodronate—SLC25A5—Disease—EGFR—bone cancer	0.000109	0.00145	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—PTGS2—bone cancer	0.000108	0.00143	CbGpPWpGaD
Clodronate—SLC25A4—Disease—MDM2—bone cancer	0.000105	0.00139	CbGpPWpGaD
Clodronate—SLC25A4—Disease—PTGS2—bone cancer	0.000101	0.00134	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—EGFR—bone cancer	9.36e-05	0.00124	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	9.31e-05	0.00123	CbGpPWpGaD
Clodronate—SLC25A6—Disease—EGFR—bone cancer	9.16e-05	0.00121	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—PTGS2—bone cancer	8.45e-05	0.00112	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	8.1e-05	0.00107	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—TP53—bone cancer	7.86e-05	0.00104	CbGpPWpGaD
Clodronate—SLC25A4—Disease—EGFR—bone cancer	7.15e-05	0.000948	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	6.36e-05	0.000844	CbGpPWpGaD
Clodronate—PTGS2—Disease—ENO2—bone cancer	5.72e-05	0.000759	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	5.34e-05	0.000708	CbGpPWpGaD
Clodronate—PTGS2—Disease—DHFR—bone cancer	5.31e-05	0.000704	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—ENO2—bone cancer	4.79e-05	0.000636	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—DHFR—bone cancer	4.45e-05	0.00059	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—GNA11—bone cancer	4.16e-05	0.000551	CbGpPWpGaD
Clodronate—PTGS2—Disease—TGFBR2—bone cancer	3.85e-05	0.00051	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CYP3A4—bone cancer	3.77e-05	0.0005	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—GSTP1—bone cancer	3.22e-05	0.000427	CbGpPWpGaD
Clodronate—PTGS2—Disease—KIT—bone cancer	2.63e-05	0.000348	CbGpPWpGaD
Clodronate—PTGS2—Disease—BRAF—bone cancer	2.47e-05	0.000327	CbGpPWpGaD
Clodronate—PTGS2—Disease—MDM2—bone cancer	2.07e-05	0.000274	CbGpPWpGaD
Clodronate—PTGS2—Disease—EGFR—bone cancer	1.41e-05	0.000187	CbGpPWpGaD
